| Cat.No. | Name | Information |
|---|---|---|
| M40769 | Anti-Mouse/Human TGF-β Antibody In vivo | This Mouse Anti-Human/Mouse TGF-β clone Clone 1D11.16.8 recognizes an epitope on Human/Mouse TGF-β1,2,3. |
| M40768 | Anti-Mouse IFNAR-1 Antibody In vivo | IFNAR1 is a type I membrane protein, that in conjunction with IFNAR2, makes up the heterodimeric receptor that binds all type I IFNs, which includes IFN α and β. |
| M40764 | Anti-Mouse PD-L1 mAb In vivo | |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M40602 | Alacizumab | Alacizumab is a monoclonal antibody against VEGFR2 that can be used in cancer-related studies. |
| M40600 | Ebronucimab | Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia. |
| M40599 | Ocrelizumab | Ocrelizumab is a humanized anti-CD20 monoclonal antibody that may be used in studies related to multiple sclerosis. |
| M40598 | Serclutamab | Serclutamab is a monoclonal antibody to EGFR that can be used in studies related to solid tumors. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
| M40595 | Pidilizumab | Pidilizumab is a humanized IgG1k anti-PD-1 monoclonal antibody that can be used in studies related to diffuse large B-cell lymphoma (DLBCL). |
| M40593 | Brolucizumab | Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). Brolucizumab can be used in studies related to macular degeneration. |
| M40592 | Certolizumab | Certolizumab is a recombinant, polyethylene glycolated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor (TNF)-alpha, and may be used in psoriasis-related studies. |
| M40552 | Osemitamab | Osemitamab (TST001) is a recombinant humanized, IgG1 antibody targeting CLDN18.2, consisting of the human mouse monoclonal TST001 γ-1 chain polymerized via disulfide bonding with the human mouse monoclonal TST001 κ-chain dimer (ACI). It can be used in studies related to bile duct tumors. |
| M31386 | Epcoritamab | Epcoritamab is a novel bispecific IgG1k/λ antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL). |
| M31300 | Faricimab | Faricimab is a bispecific antibody targeting Ang II and VEGF-A for studies related to eye disease and cardiovascular disease. |
| M31121 | Dinutuximab | Dinutuximab is an anti-disialytic ganglioside antigen (GD2) antibody with anticancer activity for studies related to pediatric neuroblastoma. |
| M25443 | Necitumumab | Necitumumab is a second-generation fully humanized immunoglobulin G1 (IgG1), epidermal growth factor (EGFR) receptor monoclonal antibody that specifically blocks the ligand binding site of EGFR. |
| M25387 | Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. |
| M25373 | Zilovertamab | Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling. |
| M25367 | Amlitelimab | Amlitelimab is a potential best-in-class (mAb) anti-OX40 ligand (OX40L) monoclonal antibody.Amlitelimab inhibits OX40-OX40L interaction and may be used in studies related to atopic dermatitis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
